COELIAC DISEASE

Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function

M G Clemente, S De Virgiliis, J S Kang, R Macatagney, M P Musu, M R Di Pierro, S Drago, M Congia, A Fasano

**Background and aims:** Despite the progress made in understanding the immunological aspects of the pathogenesis of coeliac disease (CD), the early steps that allow gliadin to cross the intestinal barrier are still largely unknown. The aim of this study was to establish whether gliadin activates a zonulin dependent enterocyte intracellular signalling pathway(s) leading to increased intestinal permeability.

**Methods:** The effect of gliadin on the enterocyte actin cytoskeleton was studied on rat intestinal epithelial (IEC-6) cell cultures by fluorescence microscopy and spectrofluorimetry. Zonulin concentration was measured on cell culture supernatants by enzyme linked immunosorbent assay. Transepithelial intestinal resistance (Rt) was measured on ex vivo intestinal tissues mounted in Ussing chambers.

**Results:** Incubation of cells with gliadin led to a reversible protein kinase C (PKC) mediated actin polymerisation temporarily coincident with zonulin release. A significant reduction in Rt was observed after gliadin addition on rabbit intestinal mucosa mounted in Ussing chambers. Pretreatment with the zonulin inhibitor FZI/0 abolished the gliadin induced actin polymerisation and Rt reduction but not zonulin release.

**Conclusions:** Gliadin induces zonulin release in intestinal epithelial cells in vitro. Activation of the zonulin pathway by PKC mediated cytoskeleton reorganisation and tight junction opening leads to a rapid increase in intestinal permeability.

**METHODS**

**IEC-6 cell cultures**

Rat intestinal epithelial cells (IEC-6 cells) were grown in cell culture flasks (Falcon Labware, Reston, Virginia, USA) at 37°C in an atmosphere of 95% air and 5% CO₂. The medium consisted of Dulbecco's modified Eagle's medium (Gibco, Rockville, Maryland, USA) containing 4500 mg/l D-glucose, pyridoxine hydrochloride, 5% heat inactivated (56°C, 30 minute) fetal bovine serum, 0.1 U/ml bovine insulin, 4 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin.

**Gliadin peptides**

Gliadin (Sigma, St Louis, Missouri, USA) was freshly prepared in a 70% ethanol solution (20 mg/ml) and used at serial dilutions in the cell culture medium, ranging from the 1:20 dilution (final concentration: gliadin 1 mg/ml; ethanol 3.5%) to the 1:200 dilution (final concentration: gliadin 0.1 mg/ml; ethanol 0.35%). The pH was adjusted to 7.4 when necessary by 1 M NaOH buffer. Similar ethanol concentrations were added to the final concentration of bovine serum albumin (BSA) and zein from maize (Sigma) used as negative controls. Ethanol concentration was never more than 3.5% in the final solution in order to avoid any direct effect of ethanol on cultured cells.

**Abbreviations:** CD, coeliac disease; Rt, transepithelial electrical resistance; Zot, zonula occludens toxin; tj, tight junctions; PKC, protein kinase C; BSA, bovine serum albumin; PBS, phosphate buffered saline; CV, coefficient of variation.
also obtained to be tested for their permeating activity in the Ussing chamber assay.

Fluorescence microscopic analysis of intracellular F-actin

Cells were washed in phosphate buffered saline (PBS) and gently detached with 2–3 minutes of exposure to 0.25% trypsin, 1 mM EDTA solution (Gibco brl). Cells (2×10⁴ cells/ml) were suspended in medium and seeded onto eight chamber slides (Nalge Nunc International) for 24 hours. Gliadin was added at increasing concentrations (0.1–1.0 mg/ml) and exposure times (15, 30, 45, 60 minutes). Cells were then washed twice in PBS, fixed in 3.7% paraformaldehyde in PBS (pH 7.4) for 15 minutes at room temperature, permeabilised with 0.5% TritonX-100 in PBS (Sigma) for 10 minutes at room temperature, and stained by incubation with 0.3 µM fluorescein phalloidin (Sigma) in PBS at 37°C for 30 minutes. After two additional washes, coverslips were mounted with glycerol-PBS (1:1) at pH 8.0. The results were analysed with a fluorescence microscope (Zeiss, Thornwood, New York, USA).

In selected experiments, gliadin was substituted with zein at a final concentration of 0.1 mg/ml.

F-actin quantitation by spectrofluorimetry

Intracellular F-actin was fluorometrically measured by spectrofluorimetry. After detaching the cells as described above, IEC-6 cells (0.2×10⁴ cells/ml medium) were seeded onto 24 well plates and cultured for 72 hours (37°C, 5% CO₂); incubation with gliadin (0.1 mg/ml) was performed for varying exposure times (15, 30, 45, 60 minutes) at 37°C and 4°C; cells were washed twice with cytoskeleton stabilisation buffer (KCl 75 mM, MgSO₄ 3 mM, ethylene glycol tetraacetic acid 1 mM, imidazole 10 mM, DTT 0.2 mM, aprotinin 10 µg/ml, PMSF 0.1 mM), fixed with 3.7% paraformaldehyde/buffer for 15 minutes, permeabilised (0.2% Triton X-100/buffer, five minutes), washed twice, and stained with NBD-phallacidin 0.3 µM for 30 minutes at room temperature; after two washes, extraction of NBD-phallacidin was initiated by addition of ice cold high pressure liquid chromatography grade methanol and continued overnight at –20°C.

Fluorescence measurements were carried out using an SLM Model 8000 spectrofluorometer (Spectronic Instruments, Inc., Rochester, New York, USA). Excitation was at 464 nm and emission was observed at 536 nm. Excitation and emission slits were set at 8 nm.

Zonulin quantitation by sandwich enzyme linked immunosorbent assay (ELISA)

A sandwich ELISA was developed in order to measure zonulin concentration in cell culture supernatants using affinity purified anti-zonula occludens toxin (Zot) antibodies, produced as previously described. Five different serial dilutions of a 200 µg/ml Zot solution (0.7, 3.1, 12.5, 50, and 200 ng/ml) were prepared in PBS-T (0.05% Tween-20 in PBS) and used to generate the standard curve. Firstly, a 10 µg/ml anti-Zot IgG solution in PBS was added to each well (100 µl/well) of a 96 well microplate. After incubation for 48 hours at +4°C, the plate was washed three times with PBS-T and blocked overnight with PBS-T (300 µl/well) containing 1% BSA. After draining the blocking solution, five Zot serial standards and the cell culture medium samples were added in duplicate (100 µl/well) and incubated for two hours at room temperature with continuous shaking. Following three washes with PBS-T, 0.5 µg/ml biotinylated anti-Zot antibody solution in PBS-BSA1%-PEG 4% was added to each well (100 µl/well) and incubated for one hour at room temperature while shaking. After washing six times in PBS-T, a 15 minute incubation was performed with extravidin (Sigma) diluted 1:16 000 in 0.1 M Tris-HCl, 1

![Figure 1](effect of gliadin [0.1 mg/ml] on IEC-6 cell cytoskeleton. (A) Fluorescence microscopy of gliadin exposed IEC-6 cells. Incubation for 15 minutes of cultured cells with gliadin caused a reorganisation of actin filaments characterised by redistribution to the cell subcortical compartment and subsequent cell rounding. A normal F-actin fluorescence pattern was observed when cells were exposed to similar concentrations of either zein, a protein from maize (B), or bovine serum albumin negative control (C). The gliadin effect on the actin cytoskeleton was reversible as two hours after withdrawal of gliadin from the culture medium the actin cytoskeleton returned to its basal state (D). Magnification: 40x.)
mM ZnCl₂, 1 mM MgCl₂). Absorbance at 405 nm was measured with a microplate autoreader (Molecular Devices, Sunnyvale, California, USA). To define the intra- and interassay precision of the ELISA sandwich method, the coefficient of variation (CV) was calculated using three replicates from two samples with different concentrations of zonulin on three consecutive days. The interassay test of the ELISA sandwich method produced CV values of 9.8%. CV of the intra-assay test was 4.2% on day 1, 3.3% on day 2, and 2.9% on day 3.

Inhibitors

To explore the gliadin activated pathway(s) leading to cytoskeleton rearrangement, experiments were performed by spectrofluorimetry with specific inhibitors, including cycloheximide (50 µg/ml), an inhibitor of protein synthesis, and CGP41251 (1 µM), a specific inhibitor of PKC. Spectrofluorimetry and Ussing chamber experiments were also performed in the presence of the synthetic peptide FZI/0 (1 µg/ml; Biopolymer Laboratories, University of Maryland, Baltimore, Maryland, USA), which specifically competes for binding of zonulin to the receptor.

Ussing chambers

Experiments were carried out as previously described. Briefly, adult male New Zealand white rabbits (2–3 kg) were sacrificed by cervical dislocation. A 20 cm segment of ileum was removed, rinsed free of the intestinal content, opened along the mesenteric border, and stripped of muscular and serosal layers. Eight sheets of mucosa so prepared were then mounted in lucite Ussing chambers, connected to a voltage clamp apparatus (EVC 4000; World Precision Instruments, Sarasota, Florida, USA), and bathed with freshly prepared buffer containing (mM): NaCl 53; KCl 5; Na₂SO₄ 30.5; mannitol 30.5; Na₂HPO₄ 1.69; NaH₂PO₄ 0.3; CaCl₂ 1.25; MgCl₂ 1.1; NaHCO₃ 25. The bathing solution was maintained at 37°C with water jacketed reservoirs connected to a constant temperature circulating pump and gassed with 95% O₂ and 5% CO₂. Poten-
tial difference was measured, and short circuit current and tissue resistance (Rt) were calculated as previously described.

Tissues were exposed to either gliadin (in the presence or absence of the zonulin inhibitor synthetic peptide FZI/0 added at a final concentration of 1 µg/ml) or two gliadin derived synthetic peptides (the non-toxic peptide AA 22–39 or the toxic peptide 31–55, final concentration 0.1 µg/ml) and the electrical parameters monitored every 10 minutes.

Statistical analysis

Student’s t test was used for both paired and unpaired analysis. Statistical significance was reached when p values were less than 0.05.

RESULTS

Fluorescence microscopic analysis of intracellular F-actin

Incubation of IEC-6 cells with gliadin led to reorganisation of intracellular actin filaments which was visible by fluorescent microscopy after only 15 minutes of gliadin incubation and
conducted in the presence or absence of the protein synthesis. To establish whether the effect of gliadin on actin polymerisation is independent of new protein synthesis, experiments were performed. The temperature of +4°C failed to inhibit the gliadin induced actin polymerisation (fig 2A). Figure 2B shows the time profile of actin polymerisation with a peak at 60 minutes. Gliadin induced a significant increase in the cellular content of F-actin quantitation by spectrofluorimetry. Two hours after withdrawal of gliadin the actin cytoskeleton returned to its basal state (fig 1D). Pretreatment with cycloheximide. Pretreatment of cells with cycloheximide (50 μg/ml for 30 minutes prior to and throughout one hour of gliadin exposure) did not inhibit gliadin induced actin polymerisation (fig 3).

Effect of gliadin on actin polymerisation is independent of new protein synthesis

To establish whether the effect of gliadin on actin polymerisation is dependent on new protein synthesis, experiments were conducted in the presence or absence of the protein synthesis inhibitor cycloheximide. Pretreatment of cells with cycloheximide (50 μg/ml for 30 minutes prior to and throughout one hour of gliadin exposure) did not inhibit gliadin induced actin polymerisation (fig 3).

Pretreatment with PKC inhibitor CGP41251

As the effect of both zonulin and Zot on actin polymerisation are PKC-α dependent, we elected to establish the effect of the PKC-α inhibitor CGP41251 on gliadin induced actin polymerisation. The effect of gliadin on F-actin was almost totally inhibited by the PKC inhibitor CGP41251 (1 μM) when added 30 minutes prior to and throughout one hour of gliadin exposure (fig 3).

Role of zonulin in gliadin induced actin polymerisation

As the effect of gliadin on the cell cytoskeleton was similar to that previously seen with both zonulin and its prokaryotic analogue Zot, we decided to determine whether gliadin induced actin polymerisation was mediated by zonulin.

Gliadin induced zonulin release from enterocytes

Zonulin concentration was measured by a sandwich ELISA in media of gliadin exposed cells at increasing time intervals. Zonulin was detectable in cell culture supernatants as soon as 15 minutes post-incubation with 0.1 mg/ml gliadin, reached a peak at 30 minutes, and returned to baseline after 60 minutes (fig 4). The amount of zonulin secreted was dependent on the...
gliadin concentration as incubation of cells with 1 mg/ml gliadin caused a peak release of zonulin of 2200 pg/ml. No detectable zonulin was found in BSA exposed cells (fig 4). Zonulin release temporally preceded and kinetically resembled the time profile of actin polymerisation following gliadin exposure (fig 2B), suggesting that gliadin induced actin polymerisation is zonulin dependent.

Effect of the zonulin inhibitor FZI/0 on gliadin dependent actin polymerisation

We have recently demonstrated that the effect of zonulin on the cell cytoskeleton and tj permeability can be inhibited by FZI/0, a synthetic peptide that mimics the zonulin binding domain and therefore blocks zonulin activated intracellular signalling. The peak of gliadin induced actin polymerisation (106.8±0.5% of baseline) was inhibited by pretreatment with FZI/0 (1 µg/ml) for 30 minutes prior to and throughout the experiment (101.8±0.5; p<0.05). Pretreatment with either the synthetic peptide FZI/0 or the PKC inhibitor CGP41251 did not inhibit zonulin release following gliadin incubation (fig 5). These results suggest that the inhibitory effect of FZI/0 on gliadin induced actin polymerisation is due to blockage of the zonulin receptor rather than an effect on zonulin release by enterocytes following gliadin exposure.

Effect of gliadin on intestinal permeability

Addition of α-gliadin to rabbit intestinal mucosa mounted in Ussing chambers led to a reduction in Rt, which became significant after 30 minutes of incubation. The same effect was observed with the gliadin toxic peptide 31–55 but not with the gliadin non-toxic peptide 22–39 (fig 6A). The gliadin permeating effect was reversible, with tissue Rt returning to baseline within 30 minutes of removal of the peptide from the mucosal bathing solution (data not shown). The effect of gliadin on Rt was inhibited by pretreatment with the synthetic peptide FZI/0 (1 µg/ml; fig 6B), suggesting that the effect of gliadin on Rt is zonulin dependent.

DISCUSSION

The intestinal epithelium is the largest mucosal surface providing an interface between the external environment and the immunocompetent host. Under physiological circumstances the intestine serves as the primary route for passive transepithelial solute flow. Healthy mature gut mucosa with its intact tj serves as the main barrier to the passage of macromolecules. Furthermore, the intestinal barrier functions as the major organ of defence against foreign antigens, toxins, and macromolecules entering the host via the oral/enteric route. During such healthy states, quantitatively small but immunologically significant fractions of antigens cross the defence barrier. These antigens are absorbed across the mucosa along two functional pathways. The vast majority of absorbed proteins (up to 90%) cross the intestinal barrier through the transepithelial pathway, followed by lysosomal degradation that converts proteins into smaller non-immunogenic peptides. The remaining portion of proteins is transported as intact molecules, resulting in antigen specific immune responses. This latter phenomenon utilises the paracellular pathway that involves subtle but sophisticated regulation of intercellular tj that can contribute to antigen oral tolerance. When the integrity of the tj system is compromised such as during prematurity or exposure to radiation, chemotherapy, and/or toxins, an immune response to environmental antigens (including autoimmunity and food allergies) may develop. The specific cells that are important for the immune response lie in close proximity to the luminal antigens and account for up to 80% of all immunoglobulin producing cells in the body. Another important factor for intestinal immunological responsiveness is the major histocompatibility complex. HLA class I and II genes are located in the major histocompatibility complex locus on chromosome 6. These genes code for glycoproteins, which bind and shuttle peptides from the cytoplasm to the cellular membrane making up the HLA-peptide complex, which is recognised by certain T cell receptors in the intestinal mucosa. Susceptibility to at least 50 diseases, including CD, has been associated with specific HLA class I or class II alleles. A common denominator of these diseases is the presence of several pre-existing conditions leading to an autoimmune process. The first component needed to develop an autoimmune process is a genetic susceptibility for the host immune system to recognise, and potentially misinterpret, an environmental antigen presented within the gastrointestinal tract. Secondly, the host must be exposed to the antigen. Finally, the antigen must be presented to the gastrointestinal mucosal immune system following its paracellular passage (normally prevented by the tj competency) from the intestinal lumen to the gut submucosa. In all cases, increased permeability appears to precede the disease and causes an abnormality in antigen delivery that triggers the multiorgan process leading to the autoimmune response.

While our knowledge of tj ultrastructure and intracellular signalling events have significantly progressed during the past decade, relatively little is known about their pathophysiological regulation secondary to extracellular stimuli. Therefore, the intimate pathogenic mechanisms of diseases in which tj are affected have remained unexplored owing to our limited understanding of the extracellular signalling involved in tj regulation. The discovery of Vibrio cholerae derived Zot has shed some light on the intricate mechanisms involved in the modulation of the intestinal paracellular pathway and has allowed us to identify an intestinal mammalian analogue that participates in tj regulation. This analogue, which we have named zonulin, represents a novel eukaryotic protein that reversibly opens intestinal tj. We have recently demonstrated that zonulin expression is increased during the early stage of CD, suggesting that the reported opening of tj at the early stage of the disease could be mediated by zonulin.

The studies reported in this paper were aimed at establishing the link between enterocyte gliadin exposure and zonulin release. The results of our study indicate that gliadin activates the zonulin signalling pathway in normal intestinal epithelial cells in vitro. The cellular response observed only a few minutes after gliadin incubation was characterised by significant cytoskeleton reorganisation with a redistribution of actin filaments mainly in the intracellular subcortical compartment. Spectrofluorimetry experiments revealed that such cytoskeleton reorganisation was associated with an increment in F-actin secondary to an increased rate of intracellular actin polymerisation. We can exclude the fact that the gliadin induced increment in F-actin was due to new protein synthesis as it was not affected by preincubation of cells with cycloheximide, a potent inhibitor of protein synthesis. An actin polymerisation dependent permeabilisation of the tj was also ruled out by the experiments performed at low temperature. Instead, inhibition of the effect of gliadin that was observed after pretreatment with a PKC inhibitor suggested that actin polymerisation was dependent on PKC intracellular signalling. Moreover, the experiments performed in Ussing chambers showed that addition of gliadin peptides to the intestinal mucosa in vitro caused a significant reduction in Rt within a few minutes. We have previously demonstrated that large proteins can cross the intestinal barrier following changes in Rt of similar magnitude (~20% decrement from baseline values) to that induced by gliadin (see fig 6). It is therefore possible to hypothesise that gliadin induced cytoskeleton reorganisation, as observed by fluorescence microscopy and spectrofluorimetry, acts on tj structural...
proteins causing changes in Rt and intestinal permeability to macromolecules, including gliadin. Interestingly, the peak of actin polymerisation detected after only 60 minutes of gliadin incubation temporarily followed zonulin release by IEC-6 cells, suggesting that this event is secondary to gliadin-dependent release of zonulin. We therefore elected to investigate whether the gliadin induced cytoskeleton effect was mediated by zonulin. We have previously demonstrated that following binding to its specific surface receptor, zonulin induces actin polymerisation, followed by cytoskeleton redistribution to the subcortical cell compartment. The cytoskeleton changes induced by zonulin are followed by TJ disassembly, leading to increased intestinal paracellular permeability. The experiments performed with the synthetic peptide FZI/0, which can compete and block zonulin binding to its receptor, showed complete inhibition of the peak of F-actin increment induced by gliadin, as well as complete inhibition of the gliadin induced reduction in intestinal Rt in vitro. However, pretreatment with the synthetic peptide failed to inhibit gliadin induced zonulin release. These results suggest that FZI/0 exerts its inhibitory effect on gliadin induced actin polymerisation by blocking the zonulin receptor rather than affecting zonulin release.

At this stage we do not know whether gliadin dependent activation of the zonulin system requires interaction of gliadin with a specific enterocyte receptor(s) or is a consequence of an unspecific response. However, the observation that gliadin induces release of zonulin and changes in Rt only when added to the mucosal aspect of the enteric epithelial cells (data not shown) suggest that the gliadin polarised effect is dependent on interaction with a surface receptor present on the brush border of the enterocyte.

Considering the results of this study and our preliminary data generated using intestinal tissues from both coeliac patients in remission and healthy controls (S Drago, A Fasano, unpublished), we can hypothesise a possible gliadin mechanism of action leading to a zonulin mediated increase in actin polymerisation and intestinal permeability. Enterocytes exposed to gliadin physiologically react by secreting zonulin in the intestinal lumen. While in normal intestinal tissues this secretion is self limited in time (see fig 4), in CD gut tissues the zonulin system is chronically upregulated, leading to a sustained increase in intestinal permeability to macromolecules, including gliadin, from the lumen to the lamina propria. Here, gliadin is deamidated by tissue transglutaminase and then recognised by HLA-DQ2/DQ8 bearing antigen presenting cells, triggering the onset of the CD autoimmune response. The experiments performed with the synthetic peptide failed to inhibit gliadin induced actin polymerisation by blocking the zonulin receptor rather than affecting zonulin release.

ACKNOWLEDGEMENTS

The work was partially supported by the National Institutes of Health grant DK-48373 (AF) and a grant from the Asessorato Igiena, Sanitá e Assistenza Sociale, Regione Autonoma della Sardegna, Cagliari and from the Ministero dell’Università e della Ricerca Scientifica e Tecnologica (quota 40%), Roma, Italy (SDV).

REFERENCES

Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function

M G Clemente, S De Virgiliis, J S Kang, R Macatagney, M P Musu, M R Di Pierro, S Drago, M Congia and A Fasano

Gut 2003 52: 218-223
doi: 10.1136/gut.52.2.218

Updated information and services can be found at:
http://gut.bmj.com/content/52/2/218

References

This article cites 27 articles, 7 of which you can access for free at:
http://gut.bmj.com/content/52/2/218#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Coeliac disease (537)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/